Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LN-145/LN-145-S1 in recurrent/metastatic HNSCC
NCT03083873Phase 2Completed
- Sponsor
- Iovance Biotherapeutics
- Start
- Jan 2017
- Primary completion
- Aug 2022
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of LN-145 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Iovance Biotherapeutics. Started Jan 2017; status: completed.
02
Drugs
LN-145
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03083873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083873.